摘要
代谢综合症,即符合任意三个如下指标:高血糖、高血压、高甘油三酯血症、低高密度脂蛋白和/或腹部肥胖,这些指标均与负健康状况相关联。例如,代谢综合症负面影响的认知;然而,代谢综合征增加的风险却了解很少,即满足1或2,而又不符合3或其他的标准。我们假设代谢综合症增加的风险会与认知和相关神经解剖学负相关,例如,记忆和海马体积,而且这种风险延伸到情感功能。119非痴呆/非抑郁的参与者(年龄=60.1+12.9;约50%的非裔美国人),按照满足代谢综合症代谢风险分组-无(0标准满足),低(1-2标准满足),或高(3+满足3个标准)。采用多元线性回归对这个三组间的认知、情感、相关的神经解剖学进行了比较。探索性分析,通过种族分组,考虑个体健康差异对代谢综合症单个指标(例如,实际的血压读数)的显著结果的分析中的作用。在控制了年龄,种族(NS)和IQ之后,指标的增加可能造成抑郁症状(无<低<高),学习和记忆的能力(无>低=高)。种族为进一步研究差异的健康对增加血管风险导致大脑衰老的影响所提供的经验支持的差异,从而不同的疾病严重程度指数导致大脑结构和功能的不同方面代谢综合征妥协情绪、认知和海马结构,增量风险适用于一些但不是所有的这些状况。治疗提供者可能监测一个更加广泛的风险因素,包括代谢综合症指标包括血压和胆固醇水平,并考虑在不同成年人群的脑行为的关系。
关键词: 影响、老化、认知、健康差异、代谢综合症、神经解剖学、血管的风险。
Current Alzheimer Research
Title:What Metabolic Syndrome Contributes to Brain Outcomes in African American & Caucasian Cohorts
Volume: 12 Issue: 7
Author(s): Melissa Lamar, Leah H. Rubin, Olusola Ajilore, Rebecca Charlton, Aifeng Zhang, Shaolin Yang, Jamie Cohen and Anand Kumar
Affiliation:
关键词: 影响、老化、认知、健康差异、代谢综合症、神经解剖学、血管的风险。
摘要: Metabolic syndrome (MetS), i.e., meeting criteria for any three of the following: hyperglycemia, hypertension, hypertriglyceridemia, low high-density lipoprotein and/or abdominal obesity, is associated with negative health outcomes. For example, MetS negatively impacts cognition; however, less is known about incremental MetS risk, i.e., meeting 1 or 2 as opposed to 3 or more criteria. We hypothesized incremental MetS risk would negatively contribute to cognition and relevant neuroanatomy, e.g., memory and hippocampal volumes, and that this risk extends to affective functioning. 119 non-demented/non-depressed participants (age=60.1+12.9;~50% African American) grouped by incremental MetSrisk–no (0 criteria met), low (1-2 criteria met), or high (3+ criteria met)–were compared across cognition, affect and relevant neuroanatomy using multivariable linear regressions. Exploratory analyses, stratified by race, consider the role of health disparities in disease severity of individual MetS component (e.g., actual blood pressure readings) on significant results from primary analyses. Incremental MetS risk contributed to depressive symptomatology (no<low<high), learning and memory performance (no>low=high) after controlling for age, race (n.s.) and IQ. Different indices of disease severity contributed to different aspects of brain structure and function by race providing empirical support for future studies of the impact distinct health disparities in vascular risk have on brain aging. MetS compromised mood, cognition and hippocampal structure with incremental risk applying to some but not all of these outcomes. Care providers may wish to monitor a broader spectrum of risk including components of MetS like blood pressure and cholesterol levels when considering brainbehavior relationships in adults from diverse populations.
Export Options
About this article
Cite this article as:
Melissa Lamar, Leah H. Rubin, Olusola Ajilore, Rebecca Charlton, Aifeng Zhang, Shaolin Yang, Jamie Cohen and Anand Kumar , What Metabolic Syndrome Contributes to Brain Outcomes in African American & Caucasian Cohorts, Current Alzheimer Research 2015; 12 (7) . https://dx.doi.org/10.2174/1567205012666150701102325
DOI https://dx.doi.org/10.2174/1567205012666150701102325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Inflammation Markers in Essential Hypertension
Medicinal Chemistry Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Current Vascular Pharmacology Acute Decompensated Heart Failure Update
Current Cardiology Reviews Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Corneal Changes in Diabetes Mellitus
Current Diabetes Reviews Review of Characteristics, Pharmacology, Determination and Pharmacokinetics of Rhaponticin
Mini-Reviews in Organic Chemistry Circulating Endothelial Progenitor Cells as Biomarkers for Prediction of Cardiovascular Outcomes
Current Medicinal Chemistry Adjunctive Therapies in Severe Pneumonia in Critical Care Patients
Infectious Disorders - Drug Targets Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease
Current Psychopharmacology Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research